Sittard, Netherlands

Guido Koopmans

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • JA Sittard, NL (2015)
  • Sittard, NL (2016 - 2019)

Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Guido Koopmans: Innovator in Neuropathic Pain Treatment

Introduction

Guido Koopmans is a notable inventor based in Sittard, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of nervous system diseases and disorders. With a total of 3 patents to his name, his work is recognized for its potential impact on healthcare.

Latest Patents

Koopmans' latest patents include innovative compounds such as 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives. These compounds are characterized by a complex formula that allows for various substitutions, making them versatile in their application. They are particularly useful in treating diseases that respond to modulation of the GABA receptor complex. Another significant patent involves the use of malononitrilamides in neuropathic pain, providing new pharmaceutical compositions aimed at alleviating neuropathic pain syndromes.

Career Highlights

Guido Koopmans is currently associated with Algiax Pharmaceuticals GmbH, where he continues to develop innovative solutions for pain management and neurological disorders. His work is pivotal in advancing therapeutic options for patients suffering from these conditions.

Collaborations

Koopmans collaborates with esteemed colleagues such as Birgit Hasse and Stefan Mullner, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Guido Koopmans stands out as a key figure in the pharmaceutical industry, with his inventions paving the way for new treatments in neuropathic pain and nervous system disorders. His contributions are vital for the ongoing development of effective therapies in this critical area of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…